✦ LIBER ✦

Dissolution Testing for Generic Drugs: An FDA Perspective

✍ Scribed by Om Anand; Lawrence X. Yu; Dale P. Conner; Barbara M. Davit

Book ID: 111767723
Publisher: American Association of Pharmaceutical Scientists
Year: 2011
Tongue: English
Weight: 349 KB
Volume: 13
Category: Article
ISSN: 1550-7416
DOI: 10.1208/s12248-011-9272-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predicting Drug–Drug Interactions: An FD

Predicting Drug–Drug Interactions: An FDA Perspective

✍ Lei Zhang; Yuanchao (Derek) Zhang; Ping Zhao; Shiew-Mei Huang 📂 Article 📅 2009 🏛 American Association of Pharmaceutical Scientists 🌐 English ⚖ 155 KB

Pediatric Drug Development in Anesthesio

Pediatric Drug Development in Anesthesiology: An FDA Perspective

✍ Rappaport, Bob A.; Schultheis, Lex W.; Mathis, Lisa L.; Roca, Rigoberto A.; Simo 📂 Article 📅 2006 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 106 KB

An FDA perspective on antiarrhythmic dru

An FDA perspective on antiarrhythmic drugs in phase II trials

✍ Raymond Lipicky 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 331 KB

Impact of compliance on drug development

Impact of compliance on drug development:: An FDA perspective

✍ M Cavaillé-Coll 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 47 KB

NerveCenter: FDA requirements for generi

NerveCenter: FDA requirements for generic drug applications

📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB

Analytical methods for dissolution testi

Analytical methods for dissolution testing of nanosized drugs

✍ Daniel Jünemann; Jennifer Dressman 📂 Article 📅 2012 🏛 Pharmaceutical Press 🌐 English ⚖ 759 KB